Episode 68
Biotech Hangout
00:00
The Negative Pushback to EQRX
I haven't heard of many examples of just returning cash to the shareholders. It's anywhere between 10 to 20% of that just goes up the window. But I think this is a very it would have been very difficult for the merger partner to raise that kind of capital without this type of transaction. And another theme coming out of the EQRX story is that there are certain people in biotech who seem to have a talent for fundraising on big vision ideas.
Transcript
Play full episode
